-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, 2021, Fuhong Henlius (2696.
HK) announced that the company has recently obtained approval from the Hong Kong Stock Exchange because it complies with the relevant requirements of the Main Board Listing Rules and will formally convert it from April 23, 2021.
The "B" mark will be removed from the stock symbol.
On September 25, 2019, Henlius successfully listed on the main board of the Stock Exchange in accordance with Chapter 18A of the Listing Rules, which kicked off the company's new phase of development, with the stock code 2696.
While accelerating the process of launching pipeline products and continuing to maximize the commercial value of biosimilar drugs, Henlius has also continued to innovate, adhering to the innovation strategy of “internal and external development”, and coordinated with the scientific research centers in China and the United States to improve R&D efficiency and build The increasingly mature differentiated innovation pipeline, and the pipeline layout led by the innovative anti-PD-1 monoclonal antibody HLX10 is becoming more abundant.
About Fuhong Henlius
Fuhong Henlius (2696.
Henlius has forwardly deployed a diversified and high-quality product pipeline, covering more than 20 innovative monoclonal antibodies, and comprehensively promoted tumor immunotherapy based on its own anti-PD-1 monoclonal antibody HLX10.
